AZN - AstraZeneca lung cancer therapy Imfinzi fails in late-stage trial
2024-06-25 10:24:44 ET
More on AstraZeneca
- AstraZeneca: The Price Upside Is Exhausted For Now (Rating Downgrade)
- AstraZeneca: Plotting A Bold Path To $80 Billion Revenues, I'm Pausing For Breath
- AstraZeneca: A Triple Shot Of Income, Growth, And Value
- AstraZeneca adds novel systemic lupus erythematosus target with BenevolentAI
- AstraZeneca breast cancer therapy fails in late-stage trial